Drug side effects
ixekizumab Side Effects
The reactions most often reported to the FDA for ixekizumab (also sold as Taltz), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 35,897
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2016 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of ixekizumab come from 35,897 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 35,897 reports to the FDA Adverse Event Reporting System (FAERS) for ixekizumab (Taltz): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
35,897
Reports Mentioning Death
529
1.5% of reports — not proof the medicine caused the death
Hospitalizations
2,822
7.9% of reports
Top Indication
Psoriasis
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 529 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 314 |
| COVID-19 | 18 |
| MYOCARDIAL INFARCTION | 18 |
| CARDIAC ARREST | 15 |
| PNEUMONIA | 15 |
| SEPTIC SHOCK | 14 |
| INFECTION | 12 |
| PSORIASIS | 12 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 11 |
| DUODENAL ULCER PERFORATION | 10 |
| HAEMOGLOBIN DECREASED | 8 |
| NEOPLASM MALIGNANT | 8 |
| CARDIAC DISORDER | 7 |
| CEREBROVASCULAR ACCIDENT | 7 |
| DYSPNOEA | 7 |
| HERPES ZOSTER | 7 |
| PULMONARY EMBOLISM | 7 |
| RENAL FAILURE | 7 |
| SEPSIS | 7 |
Reactions in Hospitalization Reports
Top reactions in 2,822 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PSORIASIS | 222 |
| CELLULITIS | 156 |
| PNEUMONIA | 152 |
| NAUSEA | 138 |
| ARTHRALGIA | 137 |
| PYREXIA | 132 |
| PAIN | 111 |
| DIARRHOEA | 108 |
| RASH | 100 |
| PRURITUS | 98 |
| FATIGUE | 94 |
| VOMITING | 92 |
| PSORIATIC ARTHROPATHY | 91 |
| COVID-19 | 89 |
| HEADACHE | 89 |
| WEIGHT DECREASED | 85 |
| CARDIAC FAILURE CONGESTIVE | 84 |
| INFECTION | 79 |
Nearby, Related Medications
What the FAERS Data Reveals About ixekizumab Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 35,897 voluntary reports linked to ixekizumab and its brand equivalents (Taltz), spanning 2016 through 2025. Of those, 529 (1.5%) listed death as an outcome and 2,822 (7.9%) involved hospitalization. The most common indication reported alongside adverse events was Psoriasis.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 39% male; age distribution skews toward 45-64, with 10,434 reports in that bracket. The single most reported reaction is injection site pain with 3,851 submissions, followed by psoriasis and injection site erythema.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to ixekizumab's 35,897.
Read our methodology - how this data is sourced, computed, and verified.